The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...
The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.
According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...
Another option is MSD's immunotherapy Keytruda (pembrolizumab) and Eisai’s Lenvima (lenvatinib), which was also given the go-ahead in 2022. The new guidance says that the Cabometyx/Opdivo ...
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast ...
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...
MI Cancer Seek is the first and only simultaneous Whole Exome and Whole Transcriptome-based assay with CDx indications for adults and pediatric patients IRVING, Texas, Nov. 6, 2024 /PRNewswire ...
The Centers for Disease Control and Prevention typically coordinates between 17 and 36 investigations of foodborne illnesses involving multiple states each week. A report is posted weekly, but ...
Melania Trump declined Jill Biden's invitation for tea at the White House as their husbands meet for the customary post-election lunch. Melania reportedly cited a scheduling conflict but sources ...